Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1			
A, part 2 (i)			
A, part 2 (ii)			
A, part 2 (iii)			
В	×		
C			
E			
F		×	
G			
	riate box(es) for each measure wolumn where applicable.)	rith a tick, and fill in	the year of last
Date: April 15, 20	12		
State Party to the Convention:JAPAN			
Date of ratification/accession to the Convention:June 8, 1982			
National point of contac	t: <u>Kiichiro IWASE, Ministr</u>	y of Foreign Affairs	of Japan

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

Form A, part 1 (i)

<1>

Exchange of data on research centres and laboratories

1. Name(s) of facility <u>RIKEN Tsukuba Institute</u>

2. Responsible public or private <u>The Institute of Physical and Chemical Research</u>

organization or company (RIKEN)

3. Location and postal address <u>3-1-1,Koyadai,Tsukuba-shi,Ibaraki,305-</u>

0074,JAPAN

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

Ministry of Education, Culture, Sports, Science and Technology

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m^2)

$2 \text{ units}, 82 \text{ m}^2 \times 2$

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Risk assessment of recombinant DNA materials using Retrovirus.

<2>

Exchange of data on research centres and laboratories

- 1. Name(s) of facility <u>Murayama Annex of National Institute of Infectious</u> <u>Diseases (former National Institute of Health)</u>
- 2. Responsible public or private organization or company

Ministry of Health, Labour and Welfare

Location and postal address

Gakuen4-7-1, Musashimurayama, Tokyo 208-0011 Japan

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

Ministry of Health, Labour and Welfare

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)

Three P4 Laboratories, Seventeen P3 Laboratories and their supporting Laboratories (2,270.36 min totals).

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

<u>Laboratory diagnosis of viral haemorrahagic fever such as Lassa, Marburg and Ebola diseases.</u> (However, such diagnosis has never been performed in these laboratories so far).

Part 2 Exchange of information on national biological defence research and development programmes

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes / No

<u>Technical Research & Development Institute (TRDI), Ministry of Defense (MOD) has conducted research on detection of biological agents and research on protective equipment.</u>

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

<1>

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

<u>Program conducted in JFY 2011 (Apr.2011-Mar.2012) by TRDI was Research on Detection of Biological Agents and Research on Protective Equipment.</u>

2. State the total funding for each programme and its source.

Approximately 110 million Japanese yen for Research on Detection of Biological Agents, and approximately 10 million Japanese yen for Research on Protective Equipment. It is sponsored by MOD

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes / No


4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?

100%

5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.

The objectives and research areas of the program for JFY 2011 were as follows:

- (1)Research on Detection of Biological Agents was primarily performed by Japan Steel Works, LTD.
- (2)Research on Protective Equipment was primarily performed by TOYOBO CO.LTD.
- 6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).



<2>

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

The Japan Ground Self-Defense Force's biological defence research and development programmes for FY 2011 includes;

- Research of molecularbiological diagnosis for biological agent casualties
- Research of aerobiology
- 2. State the total funding for each programme and its source.

Approximately 2,722,000 Japanese yen, founded by the MOD

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes / No

- 4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?
- 5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.
- 6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).
- 7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

Military Medicine Research Unit, Test & Evaluation Command, Japan Ground Self-

Defense Force

2.	Where is it located (include both address and geographical location)?		
	1-2-24, Ikejiri Setagaya-ku, Tok	yo 154-0001, Ja	pan
3.	Floor area of laboratory areas by	y containment le	vel:
BL2	Approximately 42	_ (sqM)	
BL3	0	_ (sqM)	
	<u> </u>		
Total	laboratory floor area	104	(sqM)
4.	The organizational structure of e	each facility.	
(i)	Total number of personnel		
(ii)	Division of personnel:		
Milit	ary		
Civil	ian		
(iii)	Division of personnel by categor	ry:	
Scien	ntists		
Engi	neers		
Tech	nicians		
Adm	inistrative and support staff		
(iv)	List the scientific disciplines rep	presented in the s	cientific/engineering staff.
Ph.D	. of Medicine		
(v) No	Are contractor staff working in t	the facility? If so	o, provide an approximate number.
(vi) inclu	What is (are) the source(s) of full ding indication if activity is wholl		
The I	Ministry of Defense (wholly)		
(vii)	What are the funding levels for	the following pro	ogramme areas:
Resea	arch	_ cannot be c	livided into each area _
Deve	lopment	_ cannot be c	livided into each area_
Test a	and evaluation	_cannot be c	livided into each area_

(viii) Briefly describe the publication policy of the facility: No official policy. Individually authorized by the MOD.

- (ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.) None
- 5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols.

Research and Development of medical diagnosis/treatment and prevent medicine for casualties in action.

Confidence-Building Measure "C" Encouragement of publication of results and promotion of use of knowledge

The Government of Japan maintains an open policy on the exchange of information on biological research, the results of such research being made freely available in all cases where the release is not prejudicial to vital national or commercial interests. This policy would be applied to any research subject to the reporting in Forms A and B.

Relevant information of National Institute of Infectious Disease (NIID) is available at the following sites, which are relevant scientific major journals/publications in Japan generally available to States parties.

- 1) Lists of scientific papers in English and Japanese, which are published by the staffs of National Institute of Infectious Disease (NIID), can be seen in the web site of NIID. http://www.nih.go.jp/niid/en/
- 2) NIID publishes bimonthly Japanese Journal of Infectious Diseases (JJID), the leading infectious disease journal in Japan. JJID receives more than 250 manuscripts per year from authors around the world. It has been donated to more than 75 countries. JJID is available at the journal site. http://www.nih.go.jp/niid/en/

A selected article published in the journal:

Okutani A., Tungalag H., Bazartseren B., Yamada A., Tserennorov D., Otgonchimeg I., Erdenebat A., Otgonbaatar D. and Inoue S. Molecular epidemiology of *Bacillus anthracis* isolated in Mongolia by Multiplelocus variable-number tandem-repeat analysis with 8 loci (MLVA 8). JJID. 64:345-348, 2011

Results of biological research related to the Convention such as the one below are also made freely available to States parties.

K. Fukai, K. Morioka, K. Yoshida. (2011) An experimental infection in pigs using a foot-and-mouth disease virus isolated from the 2010 epidemic in Japan. J. Vet. Med. Sci. 73(9),1207-1210 https://www.jstage.jst.go.jp/article/jvms/73/9/73_11-0063/_article

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	Yes/No	Yes/No	Yes/No	Yes/No
(b) Exports of micro- organisms ¹ and toxins	Yes/No	Yes/No	Yes/No	Yes/No
(c) Imports of microorganisms and toxins	Yes/No	Yes/No	Yes/No	Yes/No
(d) Biosafety and biosecurity	Yes/No	Yes/No	Yes/No	Yes/No

Name of legislation, regulations and other measures;

Foreign exchange and Foreign Trade Law (1948)

Law on Implementing the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction and the Other Conventions (1982)

Cabinet Order for the Enforcement of the Law on Implementing the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction (1995)

The Law Concerning the Prevention of Infections and Medical Care for Patients of Infections (1998)

10

Confidence-Building Measure "F"

<u>Declaration of past activities in offensive and/or defensive biological research and development program</u>

1. Date of entry into force of the Convention for the State Party		
<u>June 8, 1982</u>		
2. Past offensive biological research and development programmes:		
None		
3. Past defensive biological research and development programmes:		
<u>None</u>		

Confidence-Building Measure "G"

Form G

Declaration of vaccine production facilities

Declaration of Vaccine Production Facilities (UPDATED, March 2012)

	 	i	1
No.	Name of Facility		General Description of
	Traine of Lacinty	address)	the Types of Diseases Covered
11	Denka Seiken Co., Ltd	2-1-1 Nihonbashi Muromachi, Chuo-ku, Tokyo, Japan	Influenza, Tetanus, Weil's disease
2	Kitasato Daiichi Sankyo Vaccine Co.,Ltd	6-111 Arai, Kitamoto-shi, Saitama, Japan	Influenza, Rubella, Diphtheria, Tetanus, Pertussis, Measles, Mumps
3	Takeda Pharmaceutical Co.,Ltd	4-1-1 Doshomachi, Chuo-ku, Osaka, Japan	Diphtheria, Tetanus, Japanese Encephalitis, Pertussis, Measles, Mumps, Rubella
4	The Research Foundation for Microbial Diseases of Osaka University (BIKEN)	3-1 Yamadaoka, Suita-shi, Osaka, Japan	Influenza, Diphtheria, Tetanus, Varicella, Japanese Encephalitis, Pertussis, Measles, Rubella
5	The Chemo-Sero- Therapeutic Research Institute (KAKETSUKEN)	1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto, Japan	Influenza, Rabies, Diphtheria, Tetanus, Japanese Encephalitis, Pertussis, Rubella, Mumps, Hepatitis A, Hepatitis B, Smallpox
h	Japan BCG Laboratory	4-2-6 Kohinata, Bunkyo-ku, Tokyo, Japan	Tuberculosis
	Japan Poliomyelitis Research Institute	5-34-4 Kumegawa-cho, Higashimurayama- shi, Tokyo, Japan	Poliomyelitis